Phase I study of nivolumab or nivolumab/cisplatin/gemcitabine to treat unresectable/recurrent biliary tract cancer

被引：0
|
作者：
Morizane, Chigusa [1 ]
Ikeda, Masafumi [2 ]
Ueno, Makoto [3 ]
Kobayashi, Satoshi [3 ]
Ohno, Izumi [2 ]
Kondo, Shunsuke [1 ]
Okano, Naohiro [4 ]
Kimura, Keisuke [5 ]
Asada, Suguru [5 ]
Namba, Yoshinobu [5 ]
Okusaka, Takuji [1 ]
Furuse, Junji [4 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[4] Kyorin Univ, Fac Med, Mitaka, Tokyo, Japan
[5] Ono Pharmaceut Co Ltd, Osaka, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz339.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O2 - 2 - 4
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [21] Gemcitabine and cisplatin plus immunotherapy in advanced biliary tract cancer: a phase II study
    Jordan Hindson
    Nature Reviews Gastroenterology & Hepatology, 2022, 19 : 280 - 280
  • [22] A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.
    Lheureux, Stephanie
    Matei, Daniela
    Konstantinopoulos, Panagiotis A.
    Block, Matthew Stephen
    Jewell, Andrea
    Gaillard, Stephanie
    McHale, Michael S.
    McCourt, Carolyn K.
    Temkin, Sarah
    Girda, Eugenia
    Backes, Floor Jenniskens
    Werner, Theresa Louise
    Duska, Linda R.
    Kehoe, Siobhan Marie
    Wang, Lisa
    Wildman, Rachel
    Wang, Ben X.
    Ohashi, Pamela S.
    Wright, John Joseph
    Fleming, Gini F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] Cisplatin plus Gemcitabine for Biliary Tract Cancer
    Cariati, Andrea
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (02): : 192 - 192
  • [24] A multicenter phase II study of gemcitabine (GEM) in patients with unresectable biliary tract cancer.
    Funakoshi, A
    Okusaka, T
    Ishii, H
    Yamao, K
    Ohkawa, S
    Saito, H
    Saito, S
    Tsuyuguchi, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 344S - 344S
  • [25] Frequency of severe neutropenia occurring as an adverse events of gemcitabine plus cisplatin chemotherapy in patients with recurrent biliary tract cancer compared to those with unresectable biliary tract cancer.
    Fujishiro, Noriko
    Mitsunaga, Shuichi
    Shinohara, Akira
    Takeno, Misaki K.
    Funazaki, Hideki
    Kimura, Gen
    Watanabe, Kazuo
    Umemoto, Kumiko
    Sasaki, Mitsuhito
    Takahashi, Hideaki
    Imaoka, Hiroshi
    Hashimoto, Yusuke
    Ohno, Izumi
    Ikeda, Masafumi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [26] Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
    Weigt, Jochen
    Malfertheiner, Peter
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 4 (04) : 394 - 396
  • [27] Efficacy of gemcitabine in advanced unresectable biliary tract cancer
    Mehrotra, B
    Ahmed, S
    Bhargava, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 377S - 377S
  • [28] A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer
    Chen, Ming-Huang
    Chiang, Nai-Jung
    Bai, Li-Yuan
    Huang, Chien-Jui
    Chen, San-Chi
    Hsiao, Chin-Fu
    Shan, Yan-Shen
    Su, Yung-Yeh
    Chen, Li-Tzong
    ANNALS OF ONCOLOGY, 2022, 33 : S478 - S478
  • [29] Neoadjuvant nivolumab, gemcitabine and cisplatin in muscle-invasive bladder cancer: Study update
    Gupta, Shilpa
    Weight, Christopher J.
    Agarwal, Neeraj
    Gupta, Sumati
    Konety, Badrinath
    Gibb, Ewan
    Davicioni, Elai
    Thyagarajan, Bharat
    Sonpavde, Guru
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [30] A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
    Kim, Richard D.
    Chung, Vincent
    Alese, Olatunji B.
    El-Rayes, Bassell F.
    Li, Daneng
    Al-Toubah, Taymeyah E.
    Schell, Michael J.
    Zhou, Jun-Min
    Mahipal, Amit
    Kim, Baek Hui
    Kim, Dae Won
    JAMA ONCOLOGY, 2020, 6 (06) : 888 - 894
12345